Spero Therapeutics Inc (SPRO)

[make it happen]

Phase 3 end of 2023 is more than a year. Look at how much money they are hemorrhaging a quarter. Litterally like $500,000,000 million a year half a billion... $100 mill and change a quarter. It's like a broken dam that's about to break.

Phase 3 is the begginging. Still has FDA which was already declined. Then a whole ton of other processes before anything. As you mentioned it's on Spero not GSK. They are just going to file some paper work like you said "filings". They just get paid. While SPRO loses approximately 1/2 billion dollars a year.

As a delinquent stock

Do you see any positive #'s

Profitability
Operating Margin-957.08%

Management Effectiveness
Return on Assets -64.45%
Return on Equity -179.55%

Cash Flow
Operating Cash Flow -83.56M
Levered Free Cash Flow -49.85M

Growth (yoy) -61.30%
Gross Profit. -42.11M
EBITDA. -93.64M
Net Income to Common -113.27M